Loading
Life sciences · Review
International Journal of Basic & Clinical Pharmacology · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The therapy of type 2 diabetes mellitus and obesity has been changed by glucagon-like peptide-1 receptor agonists (GLP-1 RAs). However, clinical evidences suggest their therapeutic potential extends far beyond glycaemic management with major function in cardiovascular, hepatic, renal and neurological illnesses To give a complete appraisal of the emerging non-glycaemic therapeutic potential of GLP-1 RAs through a survey of the available clinical evidence and to highlight future research options in this rapidly growing field. A thorough literature search was performed in the PubMed, Scopus and Google Scholar databases from inception to November 2025. The search criteria included GLP-1 receptor agonists, semaglutide, tirzepatide, and combinations with specified therapeutic areas. Clinical trials, systematic reviews and mechanistic research of landmark importance were prioritized GLP-1 RAs have shown important cardiovascular benefits, decreasing major adverse cardiovascular events (MACE) by 20%. Tirzepatide reduced heart failure hospitalization by 38% in patients with heart failure with intact ejection fraction. These medicines show potential for decreasing hepatic steatosis and fibrosis in metabolic dysfunction-associated steatotic liver disease. Observational studies demonstrate a 48% reduction in incidence of dementia and growing evidence suggests neuroprotective effects. Other therapeutic uses are for chronic renal disease, polycystic ovary syndrome, obstructive sleep apnoea and substance use disorders. GLP-1 RAs represent a paradigm change in pharmacology, evolving from glucose-lowering to multi-organ protecting treatments. The development of multiple and triple agonists and oral non-peptide formulations will certainly greatly enhance their clinical value.